WO2002102743A3 - Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel - Google Patents

Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel Download PDF

Info

Publication number
WO2002102743A3
WO2002102743A3 PCT/DE2002/002260 DE0202260W WO02102743A3 WO 2002102743 A3 WO2002102743 A3 WO 2002102743A3 DE 0202260 W DE0202260 W DE 0202260W WO 02102743 A3 WO02102743 A3 WO 02102743A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
acetic acid
alkyl esters
amino alkyl
acid amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2002/002260
Other languages
English (en)
French (fr)
Other versions
WO2002102743A9 (de
WO2002102743A2 (de
Inventor
Rudolf-Giesbert Alken
Johann Roither
Wolf-Dietrich Huebner
Werner Hrachowina
Thomas Stabingis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEROLINA DRUG DEVELOPMENT AB
BEROLINA DRUG DEV AB
Original Assignee
BEROLINA DRUG DEVELOPMENT AB
BEROLINA DRUG DEV AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ53035202A priority Critical patent/NZ530352A/xx
Priority to JP2003505289A priority patent/JP2004534802A/ja
Priority to US10/481,153 priority patent/US20040242887A1/en
Priority to CA002451638A priority patent/CA2451638A1/en
Priority to EP02752970A priority patent/EP1397327A2/de
Priority to HU0400213A priority patent/HUP0400213A3/hu
Priority to KR10-2003-7016441A priority patent/KR20040020926A/ko
Application filed by BEROLINA DRUG DEVELOPMENT AB, BEROLINA DRUG DEV AB filed Critical BEROLINA DRUG DEVELOPMENT AB
Priority to IL15941002A priority patent/IL159410A0/xx
Publication of WO2002102743A2 publication Critical patent/WO2002102743A2/de
Publication of WO2002102743A3 publication Critical patent/WO2002102743A3/de
Priority to IS7061A priority patent/IS7061A/is
Priority to NO20035599A priority patent/NO20035599D0/no
Anticipated expiration legal-status Critical
Publication of WO2002102743A9 publication Critical patent/WO2002102743A9/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung offenbart deuterierte N-substituierte α, α-Diphenyl-α-alkoxyessigsäureaminoalkylester sowie deren physiologisch verträgliche Salze. Weiterhin betrifft die Erfindung die Verwendung deuterierter N-substituierter α, α-Diphenyl-α-alkoxyessigsäureaminoalkylester, zur Behandlung hypertoner Funktionszustände im Bereich der Harnblase sowie zur Herstellung von Arzneimitteln zur Behandlung hypertoner Funktionszustände im Bereich der Harnblase. Außerdem offenbart die Erfindung pharmazeutische Zusammensetzungen enthaltend deuterierte N-substituierte α, α-Diphenyl-α-alkoxyessigsäureaminoalkylester sowie deren physiologisch verträgliche Salze zur Behandlung hypertoner Funktionszustände im Bereich der Harnblase neben pharmazeutisch verträglichen Hilfs- und/oder Zusatzstoffen.
PCT/DE2002/002260 2001-06-17 2002-06-17 Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel Ceased WO2002102743A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
HU0400213A HUP0400213A3 (en) 2001-06-17 2002-06-17 Deuterated n-substituted and alpha-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds
JP2003505289A JP2004534802A (ja) 2001-06-17 2002-06-17 重水素化Ｎ−及びα−置換ジフェニルアルコキシ酢酸アミノアルキルエステル並びにこれを含有する医薬品
US10/481,153 US20040242887A1 (en) 2001-06-17 2002-06-17 Deuterated n-substituted and alpha-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds
CA002451638A CA2451638A1 (en) 2001-06-17 2002-06-17 Deuterated n-substituted and .alpha.-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds
EP02752970A EP1397327A2 (de) 2001-06-17 2002-06-17 Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
KR10-2003-7016441A KR20040020926A (ko) 2001-06-17 2002-06-17 중수소화된 엔-치환 및 α-치환 디페닐알콕시 아세트산아미노 알킬 에스테르 및 이 화합물을 포함한 의약품
IL15941002A IL159410A0 (en) 2001-06-17 2002-06-17 DEUTERATED N-SUBSTITUTED AND alpha-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
NZ53035202A NZ530352A (en) 2001-06-17 2002-06-17 Deuterated N-substituted and alpha-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds
IS7061A IS7061A (is) 2001-06-17 2003-11-28 Tvívetnis N-setnir og a-setnir dífenýlalkoxý ediksýru amínó alkýl esterar og lyf sem innihalda téð efnasambönd
NO20035599A NO20035599D0 (no) 2001-06-17 2003-12-16 Deutererte N-substituerte og <alfa>-substituerte difenylalkoksyeddiksyreaminoalkylestere og medikamenter inneholdende disse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129832A DE10129832A1 (de) 2001-06-17 2001-06-17 Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
DE10129832.3 2001-06-17

Publications (3)

Publication Number Publication Date
WO2002102743A2 WO2002102743A2 (de) 2002-12-27
WO2002102743A3 true WO2002102743A3 (de) 2003-03-13
WO2002102743A9 WO2002102743A9 (de) 2004-03-11

Family

ID=7688891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/002260 Ceased WO2002102743A2 (de) 2001-06-17 2002-06-17 Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel

Country Status (16)

Country Link
US (1) US20040242887A1 (de)
EP (1) EP1397327A2 (de)
JP (1) JP2004534802A (de)
KR (1) KR20040020926A (de)
CN (1) CN1516684A (de)
CA (1) CA2451638A1 (de)
CZ (1) CZ20033365A3 (de)
DE (1) DE10129832A1 (de)
HU (1) HUP0400213A3 (de)
IL (1) IL159410A0 (de)
IS (1) IS7061A (de)
NO (1) NO20035599D0 (de)
NZ (1) NZ530352A (de)
PL (1) PL367218A1 (de)
RU (1) RU2004101229A (de)
WO (1) WO2002102743A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146573A1 (en) * 2006-12-04 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted oxzolidinones
US20090209608A1 (en) * 2007-08-29 2009-08-20 Protia, Llc Deuterium-enriched asenapine
US20090062185A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched anidulafungin
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
US20090076158A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched bicalutamide
US20090075870A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched caspofungin
US20090082419A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched tegaserod
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US20120244122A1 (en) * 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
US20110129444A1 (en) * 2009-09-28 2011-06-02 Intermune, Inc Novel macrocyclic inhibitors of hepatitis c virus replication
CN102584592B (zh) * 2011-12-28 2014-10-15 李进 一种氘代的拟除虫菊酯化合物及其制备方法和应用
TR201802133T4 (tr) * 2012-01-30 2018-03-21 Taiho Pharmaceutical Co Ltd Yeni asetik asit ester bileşiği veya bunun tuzu.
WO2014025569A1 (en) * 2012-08-09 2014-02-13 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
MX2015016310A (es) 2013-05-30 2016-03-03 Taiho Pharmaceutical Co Ltd Compuestos novedoso de ester de acido bencilico fluorado y sal del mismo.
CN107445798B (zh) * 2016-06-01 2020-11-03 中国农业大学 一种α,α‐二氘代醇类化合物的合成方法
CN116078377B (zh) * 2023-03-06 2023-06-27 泽升科技(广州)有限公司 一种负载催化剂催化制备氘代苯的生产工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106642A1 (de) * 1973-03-02 1974-06-20
DE2937489A1 (de) * 1978-10-09 1980-04-17 Apogepha Veb Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6439873A (en) * 1987-08-05 1989-02-10 Sharp Kk Synchronizing signal generating circuit
CA2155002A1 (en) * 1993-01-28 1994-08-04 John H. Tinker Deuterated sevoflurane as an inhalational anesthetic
DE4343838C2 (de) * 1993-12-22 1998-07-09 Lohmann Therapie Syst Lts Deuteriertes Arzneimittel in transdermaler Applikation und Verfahren zu seiner Herstellung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106642A1 (de) * 1973-03-02 1974-06-20
DE2937489A1 (de) * 1978-10-09 1980-04-17 Apogepha Veb Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase

Also Published As

Publication number Publication date
PL367218A1 (en) 2005-02-21
CA2451638A1 (en) 2002-12-27
IS7061A (is) 2003-11-28
WO2002102743A9 (de) 2004-03-11
NZ530352A (en) 2004-12-24
US20040242887A1 (en) 2004-12-02
EP1397327A2 (de) 2004-03-17
WO2002102743A2 (de) 2002-12-27
JP2004534802A (ja) 2004-11-18
CZ20033365A3 (cs) 2004-09-15
DE10129832A1 (de) 2003-07-10
RU2004101229A (ru) 2005-06-27
KR20040020926A (ko) 2004-03-09
HUP0400213A2 (hu) 2004-07-28
CN1516684A (zh) 2004-07-28
NO20035599D0 (no) 2003-12-16
HUP0400213A3 (en) 2005-08-29
IL159410A0 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
EP1426375A3 (de) Analgetische Spiroindolderivate
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
DK1227806T3 (da) Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2002070510A3 (de) Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EP1428821A8 (de) Piperidin-4-ylamine mit analgetischer Wirksamkeit
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
JP2004520290A5 (de)
WO2005054179A3 (en) Hydroxamic acid esters and pharmaceutical use thereof
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
HUP0400548A3 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
SE0102440D0 (sv) New compound
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
WO2004058303A3 (en) Compositions of benzoquinolizine carboxylic acid antibiotic drugs
WO2001051489A3 (en) Methods for lowering uric acid levels
CA2370501A1 (en) Pharmaceutical composition for the therapy of lower urinary tract symptoms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003505289

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PV2003-3365

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020037016441

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2451638

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 159410

Country of ref document: IL

Ref document number: 028121201

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1152/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 530352

Country of ref document: NZ

Ref document number: 2002313447

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002752970

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 4,6,7,8,9, DESCRIPTION, REPLACED BY CORRECT PAGES 4,6,7,8,9; PAGES 13,15,16, CLAIMS, REPLACED BY CORRECT PAGES 13,15,16

WWP Wipo information: published in national office

Ref document number: 2002752970

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10481153

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-3365

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 720/MUMNP/2004

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 530352

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 530352

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2002752970

Country of ref document: EP